The knowledge of the fate of metal-containing nanoparticles in biological media in aqueous media is of utmost importance for the future use of these promising theranostic agents for clinical applications. A methodology based on the combination of TDA-ICP-MS and CE-ICP-MS was applied to study the degradation pathway of AGuIX, a phase 2 clinical ultrasmall gadolinium-containing nanoparticle. Nanoparticle size measurements and gadolinium speciation performed in different media (phosphate buffer, urine and serum) demonstrated an accelerated dissolution of AGuIX in serum, without any release of free gadolinium for each medium.
Keywords: Biodegradation; Capillary electrophoresis; Gadolinium containing drug; Inductively coupled plasma mass spectrometry; Taylor dispersion analysis; Ultrasmall nanoparticles.
Copyright © 2021 Elsevier B.V. All rights reserved.